Cassava Sciences: Significant Program Progress and its Expected Milestones for 2021

Cassava Sciences 2021 Focus and Momentum
Cassava Sciences (SAVA) President & CEO, Remi Barbier, informed that the firm has started 2021 with tremendous momentum led by results of a 6-month interim analysis from an open-label study of simufilam, Cassava’s drug candidate for Alzheimer’s disease. Mr. Barbier expressed his belief that the rest of the year may . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.